The **Prescription Drug Affordability Board** serves as an independent action committee dedicated to devising solutions to lowering drug prices within states. It is a powerful policy on a statewide basis.

The Board is composed of 5 members nominated by legislators in the state that are generally either patients or policy officers well versed with the prescription drug pricing issue academically and personally.

Maryland was the first state to pass PDAB legislation in 2019.

**Responsibilities of the PDAB**

- Review drugs entering the market greater than $30k for treatment a year and drugs that increase substantially in price throughout the year.
- Analyze drug costs within a specific state through a number of lenses including perspectives from local and national statistics.
- Analyze and implement upper payment limits for prescription drugs, which limit the price of a drug through the Medicaid program throughout the state.
- Review generics and biosimilars, and their increase in cost along with other drugs that are generally unaffordable for patients in Maryland.

As of January 2022, there are two states that have passed PDAB legislation, Colorado and Maryland. Learn more about PDAB legislation in your state by visiting this tracker by NASHP.